SXI Stock Analysis: Standex International | NYSE
Specialty Industrial Machinery | NYSE, USA | Market Cap: 3.760m USD | 12M Return: 48.9% | US8542311076 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 41.3M
EPS Trend: 95.0%
Qual. Beats: 1
Rev. Trend: 85.7%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Standex International Corporation (NYSE: SXI) is a diversified industrial manufacturer founded in 1955 and headquartered in Salem, New Hampshire. The company operates through five reporting segments-Electronics, Engineering Technologies, Scientific, Engraving, and Specialty Solutions-serving commercial and industrial markets in the United States and internationally.
Its product portfolio spans a wide range of niche industrial applications, including reed relays, custom electronic sensors, and transformers (marketed under brands such as Standex-Meder, Renco, and Agile Magnetics); mold texturizing and engraving tooling (Piazza Rosa, GS Engineering, Innovent); specialty temperature-controlled equipment for medical, scientific, and pharmaceutical use (American BioTech Supply, Lab Research Products, Cryosafe); net and near-net formed metal components for aerospace, defense, and energy markets (Spincraft, McStarlite); and hydraulic cylinders for trucks and specialty vehicles (Federal, Custom Hoist).
The company is classified within the Industrials sector under the GICS Industrial Machinery & Supplies & Components sub-industry, reflecting its profile as a multi-segment industrial products business serving diversified end markets. Standex uses a multi-brand strategy, with each segment operating under several legacy brand names acquired over time, and serves a broad customer base across aviation, aerospace, defense, energy, medical, and industrial sectors.
- Electronics segment margins pressured by component costs and pricing
- Aerospace and defense backlog growth lifts Engineering Technologies revenue
- Scientific segment normalizes after pandemic-era refrigeration demand surge
| Net Income: 104.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 0.53 > 1.0 |
| NWC/Revenue: 36.14% < 20% (prev 39.73%; Δ -3.59% < -1%) |
| CFO/TA 0.06 > 3% & CFO 89.5m > Net Income 104.6m |
| Net Debt (424.1m) to EBITDA (232.3m): 1.83 < 3 |
| Current Ratio: 2.40 > 1.5 & < 3 |
| Outstanding Shares: last quarter (12.1m) vs 12m ago -0.05% < -2% |
| Gross Margin: 41.73% > 18% (prev 39.31%; Δ 2.42% > 0.5%) |
| Asset Turnover: 56.56% > 50% (prev 50.43%; Δ 6.14% > 0%) |
| Interest Coverage Ratio: 6.31 > 6 (EBIT TTM 193.7m / Interest Expense TTM 30.7m) |
| A: 0.20 (Total Current Assets 551.8m - Total Current Liabilities 229.5m) / Total Assets 1.59b |
| B: 0.77 (Retained Earnings 1.22b / Total Assets 1.59b) |
| C: 0.12 (EBIT TTM 193.7m / Avg Total Assets 1.58b) |
| D: 0.91 (Book Value of Equity 755.2m / Total Liabilities 830.5m) |
| Altman-Z'' = 5.61 = AAA |
| DSRI: 0.66 (Receivables 172.9m/231.9m, Revenue 891.6m/790.1m) |
| GMI: 0.94 (GM 39.31% / 41.73%) |
| AQI: 0.94 (AQ_t 0.53 / AQ_t-1 0.56) |
| SGI: 1.13 (Revenue 891.6m / 790.1m) |
| TATA: 0.01 (NI 104.6m - CFO 89.5m) / TA 1.59b) |
| Beneish M = -3.30 (Cap -4..+1) = AA |
As of August 24, 2026, the stock is trading at USD 310.28 with a total of 63,408 shares traded. Over the past week, the price has changed by -6.31%, over one month by +0.65%, over three months by +15.25% and over the past year by +48.92%.
Current recommended Stop Loss: 293.80 (which is 5.3% or 1.4 ATR below the current price).
Standex International has received a consensus analysts rating of 4.40. Therefore, it is recommended to buy SXI.
- StrongBuy: 2
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 338.4 | 9.1% |
P/E Trailing = 35.7054
P/E Forward = 32.0513
P/S = 4.2176
P/B = 4.9793
P/EG = 0.9516
Revenue TTM = 891.6m USD
EBIT TTM = 193.7m USD
EBITDA TTM = 232.3m USD
Long Term Debt = 472.8m USD (from longTermDebt, two quarters ago)
Short Term Debt = 12.5m USD (from shortTermDebt, two quarters ago)
Debt = 602.8m USD (from shortLongTermDebtTotal, last quarter) + Leases 49.1m
Net Debt = 424.1m USD (calculated: Debt 602.8m - CCE 178.7m)
Enterprise Value = 4.18b USD (3.76b + Debt 602.8m - CCE 178.7m)
Interest Coverage Ratio = 6.31 (Ebit TTM 193.7m / Interest Expense TTM 30.7m)
EV/FCF = 83.36x (Enterprise Value 4.18b / FCF TTM 50.2m)
FCF Yield = 1.20% (FCF TTM 50.2m / Enterprise Value 4.18b)
FCF Margin = 5.63% (FCF TTM 50.2m / Revenue TTM 891.6m)
Net Margin = 11.74% (Net Income TTM 104.6m / Revenue TTM 891.6m)
Gross Margin = 41.73% ((Revenue TTM 891.6m - Cost of Revenue TTM 519.6m) / Revenue TTM)
Gross Margin QoQ = 42.69% (prev 40.93%)
Tobins Q-Ratio = 2.64 (Enterprise Value 4.18b / Total Assets 1.59b)
Interest Expense / Debt = 5.09% (Interest Expense 30.7m / Debt 602.8m)
Taxrate = 21.02% (34.3m / 162.9m)
NOPAT = 152.9m (EBIT 193.7m * (1 - 21.02%))
Current Ratio = 2.40 (Total Current Assets 551.8m / Total Current Liabilities 229.5m)
Debt / Equity = 0.80 (Debt 602.8m / totalStockholderEquity, last quarter 755.2m)
Debt / EBITDA = 1.83 (Net Debt 424.1m / EBITDA 232.3m)
Debt / FCF = 8.45 (Net Debt 424.1m / FCF TTM 50.2m)
Total Stockholder Equity = 729.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.64% (Net Income 104.6m / Total Assets 1.59b)
RoE = 14.35% (Net Income TTM 104.6m / Total Stockholder Equity 729.3m)
RoCE = 16.11% (EBIT 193.7m / Capital Employed (Equity 729.3m + L.T.Debt 472.8m))
RoIC = 11.66% (NOPAT 152.9m / Invested Capital 1.31b)
WACC = 10.45% (E(3.76b)/V(4.36b) * Re(11.48%) + D(602.8m)/V(4.36b) * Rd(5.09%) * (1-Tc(0.21)))
Discount Rate = 11.48% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 85.18 | Cagr: 0.82%
[DCF] Terminal Value 71.49% ; FCFF base≈46.6m ; Y1≈53.4m ; Y5≈78.7m
[DCF] Fair Price = 36.22 (EV 863.0m - Net Debt 424.1m = Equity 438.9m / Shares 12.1m; r=10.45% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 95.05 | EPS CAGR: 9.92% | SUE: 1.24 | # QB: 1
Revenue Correlation: 85.71 | Revenue CAGR: 8.74% | SUE: 0.33 | # QB: 0
EPS current Quarter (2026-09-30): EPS=2.33 | Chg30d=+7.59% | Revisions=+29% | Analysts=5
EPS next Quarter (2026-12-31): EPS=2.41 | Chg30d=+0.86% | Revisions=+0% | Analysts=5
EPS current Year (2027-06-30): EPS=9.96 | Chg30d=+0.00% | Revisions=+12% | GrowthEPS=+14.0% | GrowthRev=+7.0%
EPS next Year (2028-06-30): EPS=11.86 | Chg30d=-2.33% | Revisions=+40% | GrowthEPS=+19.1% | GrowthRev=+8.7%
[Analyst] Revisions Ratio: +28% (up=10, down=5)